Soluble guanylate cyclase: an old therapeutic target re-visited.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Redefining the Diagnostic and Therapeutic Landscape of Non-Small Cell Lung Cancer in the Era of Precision Medicine.Journal of clinical medicine · 2025
   Review
2. Investigation of the role of nitric oxide/soluble guanylyl cyclase pathway in ascorbic acid-mediated protection against acute kidney injury in rats.Molecular and cellular biochemistry · 2015
   Article
3. Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.PloS one · 2015
   Article
4. Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.Translational oncology · 2012
   Article
5. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.American journal of physiology. Lung cellular and molecular physiology · 2011
   Article
6. Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.American journal of physiology. Heart and circulatory physiology · 2010
   Article
7. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.American journal of physiology. Lung cellular and molecular physiology · 2009
   Article
8. Design of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a systematic approach.The Biochemical journal · 2007
   Article
9. Natriuretic peptides and therapeutic applications.Heart failure reviews · 2007
   Review
10. Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - from bench top to bedside.Current vascular pharmacology · 2007
    Review
11. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.Nature reviews. Drug discovery · 2006
    Review
12. Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases.Proceedings of the National Academy of Sciences of the United States of America · 2004
    Article
13. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.Proceedings of the National Academy of Sciences of the United States of America · 2004
    Article
14. Role of cyclic GMP on inhibition by nitric oxide donors of human eosinophil chemotaxis in vitro.British journal of pharmacology · 2004
    Article
15. Novel therapies for cyclic GMP control of vascular smooth muscle growth.American journal of therapeutics
    Review

Corrections and comments

• Comment on
  NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.2002

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as